

CLAIMS

1. Use of compounds that reduce α_2 -antiplasmin in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).
- 5 2. The use according to claim 1, wherein the compounds reduce the circulating α_2 -antiplasmin concentration.
3. The use according to claim 1, the compounds reduce the circulating α_2 -antiplasmin activity.
- 10 4. The use according to claims 1-3, wherein the compounds are α_2 -antiplasmin neutralizing antibodies or derivatives thereof.
5. The use according to claim 4, wherein the derivatives are Fab fragments or ScFv fragments.
- 15 6. The use according to claims 1-3, wherein the compounds are α_2 -antiplasmin neutralizing compounds selected from plasmin, mini-plasmin (lacking the first four kringles) or micro-plasmin (lacking all five kringles).

ADD
A₂
A

add C₂